Try our Advanced Search for more refined results
Life Sciences
-
March 04, 2026
Regeneron, Sanofi Didn't Warn About Cancer Risk, Suit Says
Regeneron Pharmaceuticals and Sanofi-Aventis were sued Tuesday in Georgia federal court by a woman who said she experienced rapid progression of cutaneous T-cell lymphoma after getting injections of dupilumab, a medication the companies sell as Dupixent as a treatment for inflammation.
-
March 04, 2026
Zantac Investor Class Action Time-Barred, Pa. Judge Rules
The maker of heartburn and acid reflux relief tablet Zantac has defeated a securities fraud class action claiming the company hid for decades the cancer risks associated with the drug, causing a stock price drop when the truth was revealed, after a Pennsylvania federal judge ruled Wednesday that the claims were untimely.
-
March 04, 2026
GAO Denies Protest Of $39.5M Defense Logistics Contract
The Defense Logistics Agency reasonably concluded that a pharmaceutical company was at fault for any missubmitted bids, the U.S. Government Accountability Office said, denying the company's protest of a $39.5 million contract for potassium chloride tablets.
-
March 04, 2026
9th Circ. Hesitant To Revive Implant Suit Against Medtronic
A Ninth Circuit panel cast doubt Wednesday on a Washington man's attempt to revive a negligence lawsuit against Medtronic for allegedly not assisting him when his spinal implant malfunctioned, hinting that his failure to find an expert witness to testify the device caused his pain may be fatal to the case.
-
March 04, 2026
DC Judge Strikes Down 340B Drug Discount Registration Rule
The U.S. Health Resources and Services Administration cannot reinstate a pre-pandemic policy requiring covered hospitals' offsite facilities to register with the agency in order to access discounted drugs under the 340B program, a D.C. federal judge ruled.
-
March 04, 2026
Sandoz Parent Targets Walmart, Southwest Generic Drug Suits
Sandoz parent company Sandoz AG contested generic drug price-fixing complaints from Southwest Airlines, Walmart, Walgreen and United Healthcare, arguing that the direct action plaintiffs cannot pursue the company in the wider Pennsylvania federal court multidistrict litigation because the Swiss firm is too far removed from its Sandoz Inc. subsidiary.
-
March 04, 2026
Buyers Finalize $58M Generic-Pricing Deal With 3 Drugmakers
Purchasers of certain generic drugs asked a Pennsylvania federal court for final approval of settlements worth a total of at least $58 million with Glenmark Pharmaceutical Inc., Greenstone LLC and Pfizer Inc. over claims the companies colluded with others to keep drug prices high.
-
March 04, 2026
Judge Sets 'Hard Deadline' To Rule On Childhood Vax Policy
A Massachusetts federal judge said Wednesday he will rule within two weeks on a closely watched request to block the Centers for Disease Control and Prevention from paring back the recommended childhood vaccine schedule.
-
March 03, 2026
Moderna To Pay At Least $950M To End COVID-19 Vax IP Fight
Moderna announced Tuesday that it will pay $950 million to resolve global patent litigation brought by Arbutus and Genevant Sciences over Moderna's COVID-19 vaccines, with no future royalties, but the company could pay as much as $2.25 billion if it loses an appeal at the Federal Circuit.
-
March 03, 2026
EPA Fights Fluoridated Water IQ Risk Finding At 9th Circ.
The U.S. Environmental Protection Agency urged the Ninth Circuit on Tuesday to reverse a ruling that the EPA's current "optimal" level of fluoride in drinking water poses an unreasonable risk of lowering children's IQ, arguing that the trial judge improperly held his ruling in abeyance for years to await more scientific evidence.
-
March 03, 2026
Calif. Sued Over Cancer Warning Law For Personal Care
Forcing makeup and personal care companies to place Proposition 65 warning labels on products containing the chemical diethanolamine, or DEA, violates the First Amendment, according to a California federal lawsuit, which argues the practice is costing companies millions.
-
March 03, 2026
BioAge Investors Lose Last Bid At Obesity Drug-Linked Suit
Biopharmaceutical company BioAge Labs Inc. has escaped a suit accusing it of damaging investors by unexpectedly halting a clinical trial for a weight loss drug, with a California federal judge finding that the court already dismissed the claim that BioAge's risk disclosures were lacking.
-
March 03, 2026
Death From Stem Cell Treatment For ALS Draws $24M Verdict
A Washington state jury awarded $24 million to the family of a patient who died just two days after what his family members described as a "worthless" spinal cord procedure to treat his ALS at a Seattle stem cell clinic.
-
March 03, 2026
Ex-FDA Leaders Rebut Contraception Rollbacks At 3rd Circ.
Former FDA commissioners argued that Trump-era religious exemptions for birth control coverage jeopardize public health and distort medical science, in an animus brief filed Monday with the Third Circuit.
-
March 03, 2026
FDA Targets Advertising For Knockoff Weight-Loss Meds
The U.S. Food and Drug Administration on Tuesday accused about 30 telehealth companies of illegally marketing compounded weight-loss and diabetes drugs, the agency's latest salvo in a crackdown on direct-to-consumer pharmaceutical advertising.
-
March 03, 2026
Sanofi Gets Approval For Interlocutory Appeal In Taxotere MDL
Pharmaceutical company Sanofi will get a chance to ask the Fifth Circuit to end multidistrict litigation claiming it failed to warn cancer patients about the risk of eye injuries caused by its chemotherapy drug Taxotere, arguing that a label ruling that allowed generic-drug makers out of the case should also apply to it.
-
March 03, 2026
Fed. Circ. Revives Challenge To Augmented Reality Surgical IP
The Federal Circuit on Tuesday partly revived a patent challenge brought by a medical technology company, overruling the Patent Trial and Appeal Board in saying that there was no motivation for one to combine the teachings of a prior patent and an informational document.
-
March 03, 2026
States Can't Duck Regeneron Counterclaims In FCA Case
Eleven states pursuing a False Claims Act case against Regeneron Pharmaceuticals over what they say were inflated reimbursements for an eye drug can't block counterclaims by the drugmaker on sovereign immunity grounds, a Massachusetts federal judge has ruled.
-
March 03, 2026
Genentech Says Biocon Importing Infringing Cancer Drugs
Biotechnology company Genentech Inc. claimed Indian firm Biocon Ltd. is importing drugs into the U.S. that infringe four Genentech patents related to a breast cancer treatment, asking the U.S. International Trade Commission to investigate and ultimately bar the imports.
-
March 03, 2026
1st Circ. Won't Revive Boston's Opioid Claims Against PBMs
Boston lost its bid to revive opioid crisis-related claims against two pharmacy benefit managers, as a First Circuit panel affirmed that the suit came years too late.
-
March 03, 2026
FTC Makes 'Significant Progress' In OptumRx, Caremark Talks
Federal Trade Commission staffers got more time Tuesday for settlement talks with OptumRx and Caremark that could end the agency's case accusing the pharmacy benefit managers of inflating insulin prices, with staffers citing considerable progress in the weeks since inking a deal with Express Scripts.
-
March 02, 2026
Abbott Beats Data Sharing Suit Over Glucose Tracking Trial
An Illinois federal judge on Monday permanently tossed a lawsuit accusing Abbott Laboratories of unlawfully sharing website visitors' personal data with Meta and Google, saying the plaintiffs can't plausibly show that their legally protected information ever left Abbott's website.
-
March 02, 2026
AI Drugmaker BioXcel Eyes $9.8M Investor Settlement
BioXcel Therapeutics Inc., an artificial intelligence-driven drugmaker, has reached a $9.8 million settlement with investors to resolve claims that the company and its top brass deceived them about compliance problems with a clinical trial for a dementia drug.
-
March 02, 2026
Epic Must Face Price Conspiracy Claims Over Gallstone Drug
Epic Pharma LLC must face the majority of suits by hospitals, insurers and other drug purchasers alleging it conspired to raise and control the price of gallstone medication ursodiol, a Pennsylvania federal judge ruled Monday.
-
March 02, 2026
Chancery Orders Receiver As EpicentRx Fails To Pay $425K
The Delaware Chancery Court on Monday appointed a limited receiver to force clinical-stage biotech company EpicentRx to satisfy outstanding advancement and sanction obligations owed to its former corporate secretary Stephen Davis, finding that repeated contempt rulings and escalating fines failed to bring the company into full compliance.
Expert Analysis
-
SDNY OpenAI Order Clarifies Preservation Standards For AI
The Southern District of New York’s recent order in the OpenAI copyright infringement litigation, denying discovery of The New York Times' artificial intelligence technology use, clarifies that traditional preservation benchmarks apply to AI content, relieving organizations from using a “keep everything” approach, says Philip Favro at Favro Law.
-
What 9th Circ.'s Rosenwald Ruling Means For Class Actions
The Ninth Circuit's recent decision in Rosenwald v. Kimberly-Clark has important implications around the Class Action Fairness Act and traditional diversity jurisdiction — both for plaintiff-side and defense-side class action litigators — and deepens the circuit split concerning the use of judicial notice to establish diversity, says Grace Schmidt at DTO Law.
-
Trends In Post-Grant Practice Since USPTO Denial Guidance
Six months after the U.S. Patent and Trademark Office updated its guidance on discretionary denial of inter partes review and post-grant review, noteworthy trends in denial statistics have emerged, warranting a reassessment of strategies for parallel proceedings, says Andrew Ramos at Bayes.
-
USPTO Under Squires: A Look At The First Month
New U.S. Patent and Trademark Office Director John Squires' opening acts — substantive and symbolic — signal a posture that is more welcoming to technological improvements and focused on rebalancing the office's gatekeeping role, say attorneys at Seyfarth.
-
Opinion
Expert Reports Can't Replace Facts In Securities Fraud Cases
The Ninth Circuit's 2023 decision in Nvidia v. Ohman Fonder — and the U.S. Supreme Court's punt on the case in 2024 — could invite the meritless securities litigation the Private Securities Litigation Reform Act was designed to prevent by substituting expert opinions for facts to substantiate complaint assertions, say attorneys at A&O Shearman.
-
Opinion
High Court, Not A Single Justice, Should Decide On Recusal
As public trust in the U.S. Supreme Court continues to decline, the court should adopt a collegial framework in which all justices decide questions of recusal together — a reform that respects both judicial independence and due process for litigants, say Michael Broyde at Emory University and Hayden Hall at the U.S. Bankruptcy Court for the District of Delaware.
-
Series
Traveling Solo Makes Me A Better Lawyer
Traveling by myself has taught me to assess risk, understand tone and stay calm in high-pressure situations, which are not only useful life skills, but the foundation of how I support my clients, says Lacey Gutierrez at Group Five Legal.
-
Latest PTAB Moves Suggest A Subtle Recalibration
Recent decisions from the Patent Trial and Appeal Board, as U.S. Patent and Trademark Office Director John Squires transitions into his new role, offer new procedural and substantive tools for patent owners in procuring patent rights and enforcing them against would-be petitioners, say attorneys at Morgan Lewis.
-
Opinion
DOJ's Tracing Rule For Pandemic Loan Fraud Is Untenable
In conducting investigations related to COVID-19 relief fraud, the government's assertion that loan proceeds are nonfungible and had to have been segregated from other funds is unsupported by underlying legislation, precedent or the language establishing similar federal relief programs, say Sharon McCarthy, Jay Nanavati and Lasya Ravulapati at Kostelanetz.
-
Del. Ruling Reaffirms High Bar To Plead Minority Control
The Delaware Court of Chancery's recent decision in Witmer v. Armistice maintains Delaware's strict approach to control and provides increased predictability for minority investors in their investment and corporate governance decisions, says Elena Davis at Ropes & Gray.
-
Series
Law School's Missed Lessons: Client Service
Law school teaches you how to interpret the law, but it doesn't teach you some of the key ways to keeping clients satisfied, lessons that I've learned in the most unexpected of places: a book on how to be a butler, says Gregory Ramos at Armstrong Teasdale.
-
How Occasional Activists Have Reshaped Proxy Fights
The sophistication and breadth of first-time activist engagement continue to shape corporate governance and strategic outcomes, as evidenced across corporate annual meetings this summer, meaning advisers should anticipate continued innovation in tactics, increased regulatory complexity, and a persistent focus on board accountability, say attorneys at MoFo.
-
What To Expect After FDA Warnings To GLP-1 Compounders
The U.S. Food and Drug Administration's recent warning letters to companies advertising compounded versions of GLP-1 medications raise questions not just about the enforcement outlook for marketing such products, but also about the future of drug compounding as a whole, say attorneys at Spencer Fane.
-
Where 4th And 9th Circ. Diverge On Trade Secret Timing
Recent Fourth and Ninth Circuit decisions have revealed a deepening circuit split over when plaintiffs must specifically define their alleged trade secrets, turning the early stages of trade secret litigation into a key battleground and elevating the importance of forum selection, say attorneys at Skadden.
-
Series
Adapting To Private Practice: 3 Tips On Finding The Right Job
After 23 years as a state and federal prosecutor, when I contemplated moving to a law firm, practicing solo or going in-house, I found there's a critical first step — deep self-reflection on what you truly want to do and where your strengths lie, says Rachael Jones at McKool Smith.